RNA editing: emerging from CRISPR’s shadow
Bio Pharma Dive
OCTOBER 22, 2024
Early study data from Wave Life Sciences suggests how editing RNA may yield viable medicines. Large and small drugmakers say such results are just the start.
Tue.Oct 22, 2024
354 
Obesity Clinical Trials: Combining Patient-Centric Care with Scientific Rigor
XTalks
OCTOBER 22, 2024
Obesity remains one of the most significant public health challenges of the 21st century, not only due to its alarming prevalence but also because of its vast implications on individual and societal health. Recent statistics from the World Health Organization (WHO) reveal that worldwide obesity has nearly tripled since 1975. The latest reports indicate that over 650 million adults and an increasing number of children and adolescents are classified as obese, highlighting a global epidemic that sp
Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Editas, changing course again, looks to partner lead CRISPR therapy
Bio Pharma Dive
OCTOBER 22, 2024
The gene editing company will focus on “in vivo” medicines, while seeking to license out or find a development partner for its clinical-stage treatment reni-cel.
MangoRx hits back at Eli Lilly’s weight loss drug copycat claims
Pharmaceutical Technology
OCTOBER 22, 2024
Eli Lilly sued three online vendors and medical spas earlier this week over improper copying of tirzepatide.
Bridging Innovation & Patient Care: The Growing Role of AI
Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Starboard makes case for change at Pfizer, citing research, M&A missteps
Bio Pharma Dive
OCTOBER 22, 2024
The activist investor claims Pfizer failed to capitalize on the windfall earned from its COVID-19 vaccine and, in the process, destroyed tens of billions of dollars in market value.
Editas and Genevant team up to develop gene editing therapies
Pharmaceutical Technology
OCTOBER 22, 2024
Editas is partnering its CRISPR platform with Genevant’s LNP technology to develop novel gene editing medicines in a deal worth $283m.
Sign up to get articles personalized to your interests!
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
More Trending
Otsuka’s startup bet pays off with kidney disease drug results
Bio Pharma Dive
OCTOBER 22, 2024
A medicine the pharma acquired in a $430 million buyout of Visterra in 2018 succeeded in a Phase 3 trial in IgA nephropathy, a crowded corner of drug research.
Novo Nordisk plans label expansion for Rybelsus following Phase III win
Pharmaceutical Technology
OCTOBER 22, 2024
The oral semaglutide reduced the occurrence of major adverse cardiovascular events (MACE) by 14% in patients with type 2 diabetes.
FDA names Tarver as new head of device center
Bio Pharma Dive
OCTOBER 22, 2024
Michelle Tarver will officially replace longtime CDRH leader Jeff Shuren, who stepped down from the role earlier this year.
How pharma leaders are approaching digital transformation
Pharmaceutical Technology
OCTOBER 22, 2024
For firms unsure about the digital transition, partnering with experienced providers like Controlant simplifies the process
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Valneva Scotland announces year-long support for local cancer charity Team Jak
Pharma Times
OCTOBER 22, 2024
The company’s workforce will volunteer and fundraise for Team Jak throughout the year
Cambridge University and GSK sign immunology R&D collaboration
Pharmaceutical Technology
OCTOBER 22, 2024
GSK has announced a £50m ($54.3m) investment in a partnership with the University of Cambridge to expedite R&D in immune-related diseases.
Starboard wants to hold Pfizer leadership 'accountable' for overpaid M&A deals, poor return on R&D investment
Fierce Pharma
OCTOBER 22, 2024
Activist investor Starboard Value is baring its teeth at Pfizer management, more openly going after CEO Albert Bourla’s job. | Activist investor Starboard Value is baring its teeth at Pfizer management, more openly going after CEO Albert Bourla’s job in a new presentation.
Gilead and MSD to advance once-weekly HIV treatment to Phase III
Pharmaceutical Technology
OCTOBER 22, 2024
The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.
DOJ challenges Johnson & Johnson's talc bankruptcy attempt in Texas
Fierce Pharma
OCTOBER 22, 2024
With Johnson & Johnson sweetening the pot and mustering up the support of 83% of those who claim that the company’s talc products caused their cancer, it had
Navigating clinical trial disruption: growing trends and new technologies
Pharmaceutical Technology
OCTOBER 22, 2024
Disruption is a pressing problem in the pharmaceutical world; patient health depends on clinical trial organisers avoiding it
Seven pillars of GenAI for enterprise-level value generation
pharmaphorum
OCTOBER 22, 2024
Discover the seven essential pillars of GenAI for generating value at an enterprise level and leveraging artificial intelligence to drive innovation and growth.
World Osteoporosis Day calls for urgent action to prevent fragility fractures
Pharmaceutical Technology
OCTOBER 22, 2024
The IOF highlights the importance of collaborative efforts in treating osteoporosis, ensuring appropriate care globally.
The New Age of Decentralized Clinical Trials
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
France warns of penalties if Opella production goes offshore
pharmaphorum
OCTOBER 22, 2024
Sanofi is now in exclusive talks with private equity company Clayton Dubilier & Rice over the sale of a controlling stake in its consumer health business Opella, as the French government seeks guarantees it will keep production and jobs in France.
Avacta partners Tempus AI to boost cancer therapy development
Pharmaceutical Technology
OCTOBER 22, 2024
Avacta Therapeutics has entered a strategic collaboration with Tempus AI to advance the development of drugs in oncology.
FDA Approves Gastric Cancer Drug Vyloy, First-In-Class Approval for Astellas
XTalks
OCTOBER 22, 2024
Astellas Pharma has won approval from the US Food and Drug Administration (FDA) for Vyloy (zolbetuximab) as a first-line treatment for adults with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma. The drug is specifically indicated for patients whose tumors are HER2-negative and express claudin 18.2 (CLDN18.2). Vyloy is a first-in-class monoclonal antibody that targets the CLDN18.2 transmembrane tight junction protein, which is commonly found in some gastric and GEJ cancers.
Europe's share of clinical trials falling, with China rising
pharmaphorum
OCTOBER 22, 2024
The proportion of commercially sponsored clinical trials run in Europe almost halved over the last 10 years and is now trailing China
MacroGenics passes off struggling breast cancer med Margenza to TerSera for $40M plus milestones
Fierce Pharma
OCTOBER 22, 2024
MacroGenics’ first commercial product, breast cancer drug Margenza, is heading off to TerSera Therapeutics through a $40 million hand-off. | The 2020-approved breast cancer med booked $17.9 million in 2023 sales as it struggled to make a mark in the crowded market.
Starboard spells out its concerns with Pfizer's direction
pharmaphorum
OCTOBER 22, 2024
Starboard Value CEO Jeff Smith pulls no punches in his assessment of Pfizer failings, which he claims have resulted in at least $20bn in lost value
Telix unveils radiopharmaceutical spinoff Rhine Pharma following string of nuclear medicine acquisitions
Fierce Pharma
OCTOBER 22, 2024
There’s no denying it: the radiopharmaceuticals boom is here to stay. | Telix on Tuesday unveiled the spin-off of Rhine Pharma—a new entity born from a collaboration between Telix and Germany’s Heidelberg University Hospital—which is setting out on a mission to expand access to radiopharmaceuticals for cancer treatment and imaging.
Scaling Success: Transforming Pharma Marketing With Data-Driven Insights
Intouch Solutions
OCTOBER 22, 2024
In the dynamic world of pharmaceutical marketing, staying ahead requires innovation and advanced data analytics to provide valuable insights and achieve brand success. Joey Morrissey, Senior Director, Analytics, recently presented various data and analytics business use cases during a webinar with Salesforce highlighting how EVERSANA INTOUCH drives business impact using Tableau Pulse.
The New Age of Decentralized Clinical Trials
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Amid geopolitical risk, Legend sheds Genscript as majority shareholder
Fierce Pharma
OCTOBER 22, 2024
Legend Biotech has managed to remove Genscript Biotech as its majority shareholder, just as the former parent’s Chinese background falls under a U.S. biosecurity microscope. | Legend Biotech has managed to remove Genscript Biotech as its majority shareholder, just as the former parent’s Chinese background falls under a U.S. biosecurity microscope.
Access Insights 2024: The State of Retail Pharmacy
Pharmaceutical Commerce
OCTOBER 22, 2024
Bill Roth, General Manager, Managing Partner, Blue Fin Group, discusses key takeaways of the breakout session.
Adcentrx gets FDA clearance for phase 1 trial of ADC for tumors
BioPharma Reporter
OCTOBER 22, 2024
The FDA has given clearance to Adcentrx Therapeuticsâ IND application for an antibody-drug conjugate (ADC) targeting solid tumors.
Pharma Pulse 10/22/24: Blood Vessels Grown in a Lab, How Much Family Caregivers Would Make if Paid a Salary & more
Pharmaceutical Commerce
OCTOBER 22, 2024
The latest news for pharma industry insiders.
Unlocking Excellence: How Catalent Is Transforming Japan’s Clinical Research
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Let's personalize your content